Peptide evidence review

What the research actually shows about TB-500

Like BPC-157, the peptide it is most often stacked with, TB-500 has a broad and reproducible animal-research record and an almost empty human one. The laboratory and animal story for thymosin beta-4, the molecule TB-500 is named after, runs across cardiac, wound, eye, and nerve healing and is genuinely interesting. The human story is different. Real human trials of thymosin beta-4 do exist, but they tested a different, full-length form of the molecule in unrelated conditions like dry eye, and the adequately powered ones did not meet their primary endpoints. For the use TB-500 is actually injected for, healing tendons and muscle and speeding recovery, there is no published human evidence at all. It is not approved by the FDA, which lists it as a possible significant safety risk and says it has no human exposure data for the substance, and it is banned in sport at all times.

The honest read

TB-500 has a broad animal-research record and an almost empty human one, and that gap is the whole tension of this compound. It is the gray-market name for thymosin beta-4, and the distance between what it is sold for and what has been shown in people is wide. The laboratory and animal record is broad and, in places, genuinely interesting: thymosin beta-4 helps animals recover from heart, skin, eye, and nerve injury, and it does so through a clear effect on the cell's actin machinery. The human record is a different story, and it is the one the marketing skips. If that shape sounds familiar, it should: TB-500 is the closest analog to BPC-157, the peptide it is most often injected alongside. Both are animal-strong and human-empty, and the community sells them together as a healing stack.

Three facts decide how to read this compound. First, the human trials that exist studied a different, full-length form of thymosin beta-4, not the short fragment the FDA names as "TB-500," and they were run for unrelated conditions like dry eye and skin ulcers, not for athletic recovery. Second, the adequately powered ones did not meet their primary endpoints, and the single largest trial was never published. Third, for the use TB-500 is actually injected for, healing tendons and muscle and speeding recovery, there is no published human evidence at all. The clearest study of that exact use is one experiment in rats.

The rest of the honest read is regulatory. TB-500 is not approved by the FDA, which has placed it on a list of bulk substances for compounding that may present significant safety risks and has stated plainly that it has not identified any human exposure data for the substance. It is banned in sport at all times under the World Anti-Doping Agency list, named there by example. This piece grades each claim by the strength of the evidence behind it, keeps the full-length molecule and the marketed fragment separate, separates animal findings from human ones, and surfaces the safety and regulatory status you would want before any conversation with a clinician.

What TB-500 is and how it is thought to work

Thymosin beta-4 is a small peptide of forty-three amino acids that nearly every cell in the body already makes. Its everyday job is to manage actin, one of the proteins that gives a cell its shape and lets it move, and that single function sits underneath most of the effects researchers have studied: when cells can migrate and reorganize, tissues can repair. A cleavage product of the peptide, a short fragment called Ac-SDKP, is independently active on blood-vessel growth and on scarring, and some of the cardiac and anti-fibrotic findings are attributed to it rather than to the parent molecule (Wang et al. 2004).

There is an important naming problem here, and it is the first thing a careful reader should hold onto. The pharmaceutical research used full-length thymosin beta-4. The product sold as "TB-500" is, by the FDA's own description, a short fragment of the peptide (the sequence LKKTETQ), and because it travels through the unregulated research-chemical market, what is actually in a given vial is not guaranteed to be either the fragment or the full molecule. Human data gathered on the full-length pharmaceutical form does not automatically transfer to the fragment people inject. Keeping those two apart is most of the honest read of this compound.

The mechanisms attributed to thymosin beta-4 are real findings, and they share one feature worth keeping in mind: they were demonstrated in animals or in isolated cells, not in living human tissue. In cultured human endothelial cells, the peptide drives directional cell migration, the cellular basis for new blood-vessel growth (Malinda et al. 1997). In mouse hearts after a coronary artery was tied off, it formed a complex with the proteins PINCH and integrin-linked kinase, activated the survival signal Akt, improved cell survival, and improved heart function (Bock-Marquette et al. 2004). In the developing and injured heart it mobilizes a population of progenitor cells from the outer heart layer and promotes new vessels (Smart et al. 2007). Researchers have also mapped which part of the molecule does the cardiac work, a question that matters precisely because the gray-market product is a fragment (Hinkel et al. 2015).

Two honest caveats travel with that mechanistic story. The model is the first: a pathway shown in a mouse heart or a dish of cells is a reason to investigate, not a demonstrated effect in a person. The concentration of the evidence is the second: a large share of the strongest cardiac work comes from a small number of founding research groups, some with commercial ties to the molecule's development (Goldstein et al. 2012). Interesting is the right word for the mechanism. Settled is not.

What the research actually shows, graded by evidence tier

Here is the split that matters most, stated plainly. The preclinical record for thymosin beta-4 is large, easily more than a hundred published animal and laboratory studies across the heart, skin, eye, brain, and other tissues. The human record is roughly eight published trials, every one of them in a condition unrelated to athletic recovery, and the use TB-500 is marketed for has never been tested in a person. So the picture is a broad, reproducible animal record sitting on top of an almost empty human one for the thing buyers actually want.

The sections below walk each major use at its own tier, and they keep returning to the same two questions: was this the full-length molecule or the fragment, and was it an animal or a human.

Cardiac repair: the deepest preclinical line, all in animals

The most-developed part of the thymosin beta-4 story is the heart, and it is in animals. In mouse and rat models of heart attack, the peptide improved heart function, helped heart-muscle cells survive, reduced scarring, and encouraged new blood vessels (Bock-Marquette et al. 2004; Srivastava et al. 2007). It reactivates progenitor cells in the adult heart (Smart et al. 2007), has been linked to the heart growing new muscle cells after injury (Smart et al. 2011), and is an essential factor in a related cell-therapy form of heart protection (Hinkel et al. 2008). This is a serious body of animal work, and it is the reason the molecule has been taken seriously enough to develop as a drug.

It is also where the human gap is starkest. The company that developed an injectable thymosin beta-4 for heart attack registered the trials, then withdrew the entire program before a single patient was enrolled, citing manufacturing problems. The indication that drives the gray-market belief that this molecule heals the body from the inside was never tested in people. One recent study reported a human arm in heart-attack patients alongside its mouse work, but it is industry-affiliated and has not been independently appraised, so it should be read as a signal to watch, not as a settled human result (Zhang et al. 2025).

Wound, skin, eye, nerve, and hair: a broad animal record

The same pattern repeats across other tissues. Topical thymosin beta-4 accelerated skin-wound healing in rats and in diabetic mice (Malinda et al. 1999; Philp et al. 2003). It promoted corneal healing in animal eyes, the line of work that later reached human ophthalmic trials (Sosne et al. 2001). It improved recovery in rat models of traumatic brain injury and stroke (Xiong et al. 2012; Morris et al. 2017), and it grew hair in rodents by activating hair-follicle stem cells (Philp et al. 2004). In the lung it protected mice from a chemically induced scarring injury (Conte et al. 2013).

Two cautions belong with this list. The neuro and hair findings come largely from single research groups, which is exactly the situation where independent replication matters most and is least available. And the anti-fibrotic story is not even internally consistent: in the liver, one well-controlled program found the opposite of the anti-scarring claim, reporting that removing the animal's own thymosin beta-4 reduced fibrosis rather than worsening it (Kim et al. 2023). When the same molecule looks protective in one organ and harmful in another, the honest description is unsettled, not beneficial.

Musculoskeletal recovery: the marketed use, the thinnest evidence

This is the headline use. Athletes inject TB-500 to heal tendons, ligaments, and muscle and to recover faster, and it is the least-supported claim on this page. There is no human trial for it. The clearest direct evidence is a single study in which thymosin beta-4 improved the healing of a deliberately injured knee ligament in rats (Xu et al. 2013). The rest is laboratory scaffold work and dental-tissue cell studies, plus the observation that the peptide circulates at higher levels with exercise, which is a discovery about the body's own biology, not a demonstration that injecting more of it speeds recovery (Gonzalez-Franquesa et al. 2021).

The honest framing is direct: the popular idea that injecting TB-500 heals tendons and muscle in people is an extrapolation from general animal wound biology and one rat ligament experiment. An independent 2026 sports-medicine review reached the same conclusion, finding that thymosin beta-4 and TB-500 promoted tissue repair in preclinical models but that human orthopedic data are lacking and that the indications, dose, frequency, and duration of any use remain unknown (Mayfield et al. 2026). The marketing is far ahead of the evidence.

The human trials: real, but in other conditions, and the big ones failed

Unlike many gray-market peptides, thymosin beta-4 has genuine human trials, so they deserve a careful read. They cluster in eye disease and wound care, and they used the full-length pharmaceutical molecule.

In dry eye, a small early trial of about nine patients reported benefit (Sosne et al. 2015), but the larger, better-controlled trial of seventy-two patients missed both of its main endpoints (Sosne and Ousler 2015). In neurotrophic keratopathy, a corneal nerve disease, the trial labeled Phase III was stopped early at eighteen patients and missed its primary endpoint, reaching only a non-significant trend (Sosne et al. 2022). A 2025 Cochrane systematic review, the highest tier of evidence, looked at that data and concluded the peptide may not improve corneal healing, with a result that statistically crosses no effect (Kruoch et al. 2025). A topical wound trial in venous leg ulcers found only a suggestive, dose-finding signal, not a confirmatory result (Guarnera et al. 2010), and a small uncontrolled case series described use in stubborn corneal defects (Dunn et al. 2010).

Two more points complete the human picture. The healthy-volunteer studies that do exist tested only safety and how the body processes the drug, not whether it works, and they were intravenous infusions in a clinic, a different molecule and a different setting than self-injected TB-500 (Ruff et al. 2010; Wang et al. 2021). And one heart-failure study often cited as human cardiac evidence did not give the peptide at all; it measured the body's own thymosin beta-4 as a marker (Choudry et al. 2015). The largest and best-powered human trials, a set of late-stage dry-eye studies enrolling more than fifteen hundred patients combined, were completed but never published in the medical literature, and the sponsor disclosed that they missed their main endpoints. When the strongest human data sits outside peer review and what was disclosed is unfavorable, that absence is itself information.

Safety and what we don't know

The honest framing on safety is uncomfortable and important: there is no published human safety data for TB-500, the fragment people actually inject. The FDA said as much directly, stating that it has not identified any human exposure data for the substance and that it cannot characterize whether the drug would cause harm. That is a regulator looking at the same evidence and concluding the question is open.

Human trials of the full-length pharmaceutical molecule did report good tolerability, with no serious adverse events in healthy volunteers (Ruff et al. 2010; Wang et al. 2021). Those results do not carry over to TB-500, for four reasons. The molecule is different, full-length in the trials versus a fragment in the product. The setting is different, a supervised intravenous infusion in a clinic versus unsupervised self-injection. The use is different, with no established indication, dose, frequency, or duration for recovery (Mayfield et al. 2026). And the supply is different: the research-chemical market is unregulated, and the FDA specifically flagged risks of immunogenic reactions from peptide aggregation and of peptide-related impurities. A clean tolerability reading of a pharmaceutical-grade infusion is not evidence that an unregulated fragment injected at home is well tolerated.

Because no regulated label exists, there are no established human contraindications or drug-interaction data for TB-500; the honest answer for pregnancy, a history of cancer, or other medications is unknown. One mechanism-based concern is worth naming as a hypothesis rather than a finding: thymosin beta-4 promotes new blood-vessel growth, and any agent that does that raises a theoretical question about feeding the growth of an undetected tumor. That is a reason for caution and study, not a demonstrated human harm. The injection itself carries the ordinary risks of any non-sterile self-administered shot, including infection.

FDA status and anti-doping (WADA) status

The regulatory picture is the part of the TB-500 story the marketing tends to skip, so it leads here.

First, FDA status. TB-500 is not approved by the FDA for any use, and it is not a lawful dietary supplement, because it is a drug substance rather than a dietary ingredient. The FDA has placed it in Category 2 of its 503A list of bulk drug substances for compounding that may present significant safety risks, naming the entry as the thymosin beta-4 fragment also known as TB-500, with the page content current as of the 2026 update (U.S. Food and Drug Administration 503A list). The agency's stated basis is notable: it has not identified any human exposure data and flags immunogenicity and impurity concerns. In plain terms, it is unapproved, it is not eligible for pharmacy compounding, and it is sold online as a research chemical labeled not for human consumption.

Second, anti-doping status. TB-500 is prohibited under the World Anti-Doping Agency Prohibited List, in the growth-factors section, prohibited at all times, in and out of competition, on the 2026 list effective the first of January 2026 (World Anti-Doping Agency). It is named there by example rather than swept in by a general clause, which removes any ambiguity for an athlete. It is also detectable; anti-doping laboratories have published methods to find TB-500 and its breakdown products (Rahaman et al. 2024). Any athlete subject to testing who uses it commits a violation, and that belongs prominently in front of anyone who competes.

How and when to think about using TB-500

Vague "ask your doctor" is not useful, so here is the specific version, and for TB-500 the specific version starts with an honest hard stop. There is no evidence-based dose, because there is no human trial of the injected product for anything, and none at all for the recovery use it is sold for. Every dose, route, and schedule you will see quoted comes from animal experiments, from the human trials of a different full-length molecule that mostly failed, or from what people and sellers report doing, not from anything tested for safety or efficacy in a person using TB-500. We are not going to hand you a protocol the evidence does not support. What we can do is lay out how to think about the decision, and report, in the next section, what is actually done, so you are deciding with open eyes rather than from a vendor's pitch.

The decision factors are the ones already on this page, lined up, and for the marketed use they line up worse than they do for most peptides. The upside is animal-grade and, for tendon and muscle recovery specifically, thinner than that: a single rat ligament study plus an extrapolation from general wound biology, with zero human recovery data. The safety is unknown: the FDA states it has not identified any human exposure data for the substance and flags immunogenicity and impurity risks, and the clean tolerability seen in the old infusion trials was a different molecule given a different way. The supply is unregulated and carries an extra problem unique to this compound: the FDA names the listed substance as a short fragment, the human trials used the full-length peptide, and what is actually in a given vial is not guaranteed to be either one. The legal and sport status is settled and against use: not FDA-approved, not lawfully compoundable, banned in sport at all times and detectable.

Some "when not" answers are clear enough to state plainly. If you have a personal history of cancer, the pro-angiogenic mechanism described earlier on this page is a theoretical reason to steer clear, the same caution that applies to its stack partner. If you are subject to anti-doping testing, this is a banned, detectable substance and the answer is no. If you cannot verify what is actually in the vial with a batch-specific certificate of analysis, you are dosing an unknown, and for TB-500 you may not even know which molecule you are dosing. And if you are pregnant or breastfeeding, there is no safety data and no reason to assume any.

If, knowing all of that, you still want to understand what real-world use looks like, the next section reports it, with the risks named and without a recommendation attached.

What people and clinics actually do with TB-500 (and what we can't tell you)

The line that governs everything below: there is no approved clinical dose for TB-500, and no human trial has ever tested a dose, a route, or a duration of the injected product for recovery. Everything in this section is what people report doing in community forums and what some sellers publish. It is not a recommendation, it has not been validated, and it is the weakest tier of evidence on this page, weaker even than the thin reporting that exists for BPC-157. We include it because pretending the real-world use doesn't exist doesn't make anyone safer. Understanding it, with the risks named, does.

The stack is the whole story. TB-500 is rarely discussed on its own. It is the other half of the pairing the community calls the "Wolverine stack," TB-500 plus BPC-157, injected at separate sites, with TB-500 dosed less often than BPC-157. That pairing, not any standalone TB-500 protocol, is what most reported use actually looks like. The general shape people describe for the TB-500 side is a loading period of a few weeks followed by a lighter maintenance phase, dosed on the order of once or twice a week rather than daily, which is the main way it differs from the more-frequent BPC-157 dosing it is paired with. By subcutaneous injection is the usual route.

Why we are not quoting you a number. We can report the stack relationship and that loose weekly-ish loading-then-maintenance shape, because those recur consistently enough across sources to describe honestly. We are deliberately not quoting a specific TB-500 milligram figure, and the reason is itself the disclosure: the numbers that circulate for TB-500 are thinner and more vendor-circular than BPC-157's, they trace almost entirely to peptide-selling pages echoing each other rather than to any study or independent source, and pinning a precise dose to that would dress up an echo chamber as if it were guidance. When the only sources for a number are the people selling the vial, the honest move is to name that and stop, not to repeat the figure.

What the community itself flags. The forums are not naive, and on TB-500 their first concern is the supply. Because TB-500 sells as an unregulated research chemical and the FDA names it as a fragment of uncertain identity, experienced users treat source quality as the number-one risk, reconstitute with bacteriostatic water, and demand batch-specific third-party purity testing, a certificate of analysis, before using anything, knowing that even a clean test cannot fully resolve whether the vial holds the fragment, the full molecule, or something else. The community also raises the theoretical cancer concern, that thymosin beta-4 promotes blood-vessel growth in animal and cell studies, which in principle could feed an existing tumor, so anyone with a cancer history is told to steer clear; the complete absence of long-term human safety data for the actual product; and the ordinary risks of any self-administered injection. It is also banned in sport at all times and is detectable.

What we can't tell you, honestly. Several cautions sit on top of everything above. We could not read the primary forum threads directly, because Reddit blocks automated access, so what reporting exists comes through secondary write-ups that summarize those threads. The seller "protocols" online repeat each other's framing, so the apparent agreement on the stack and the loading-then-maintenance shape is partly an echo chamber, not independent confirmation, and that is doubly true for TB-500, where almost nothing traces back to a study. Read the consistency as the story the market tells itself, not as evidence the practice is right or safe. We also found vendor pages citing suspiciously precise safety and dosing statistics, and we have left those out because they appear fabricated.

If you are going to explore it anyway, the harm-reduction version is straightforward: do it with a clinician who knows your history and can run baseline bloodwork, insist on a real certificate of analysis for the exact batch, and understand that you are the experiment twice over, because the human data that would tell you whether this works, or is safe over time, does not exist, and because you cannot be sure which molecule the vial even contains. And if the honest answer for your situation is "not worth it," that is a legitimate place to land.

What the evidence implies clinically

By Dr. Sam Walters, NMD, Medical Director

When I read a literature like this one, the first thing I do is separate the molecule that was studied from the molecule that is sold, and for thymosin beta-4 that single distinction does most of the work. The published human trials used a full-length, pharmaceutical-grade peptide and ran it for eye and wound conditions, under supervision, by infusion. What is sold as TB-500 is a fragment of uncertain identity, injected at home, for recovery. The evidence and the product are not the same thing, and a careful reader should not let the existence of real trials launder a use those trials never examined.

The second thing I weigh is direction and depth together. The animal record here is broader and, in the heart, more sophisticated than for most peptides in this market, which is a fair reason for researchers to keep studying it. Depth in animals is not the same as a result in people, and the human evidence runs the other way: the better-powered trials missed their endpoints, the largest was never published, and the injectable program aimed at the body that the marketing celebrates was shut down before it enrolled anyone. For the tendon-and-muscle recovery use specifically, the human evidence is not thin, it is absent, and a single rat ligament study is not a foundation a person should build an injection decision on.

So the read I would bring to any conversation about it is plain. The biology is interesting and worth following in the literature. The case that injecting this fragment helps a human recover from injury has not been made, the safety of the actual product is uncharacterized by the regulator's own account, and it is banned in sport. This is one clinician's reading of the published evidence, not a substitute for a conversation with your own prescriber about your situation.

The honest close

For TB-500, the evidence supports a precise and limited description: a broad, reproducible body of animal research on tissue repair, a handful of human trials in unrelated conditions where the better-powered ones failed, no published human evidence for the recovery use it is sold for, no human safety data on the actual product, an FDA listing as a possible significant safety risk, and a standing ban in sport. The preclinical promise is real and worth following as research. The human case for the marketed use is not made, and the safety case has not been started.

For most people asking whether to inject TB-500 to recover faster, the honest read is that the evidence does not support it yet, and a careful reader should treat it as a compound to watch in the literature rather than one to use now.

We do not recommend a dose for you, and we do not tell you to use this. We report what is actually done in research and in practice, including the stack it is sold as part of, and we synthesize the evidence so you can have an informed conversation with your clinician, and when the honest read is "not yet" or "probably not worth it for you," we say so.

This content is for informational purposes and is not medical advice. Consult a licensed practitioner before changing any therapeutic protocol.

We don’t prescribe. We synthesize the research so you can have an informed conversation with your prescriber. And if the honest read of the evidence is “not yet” or “probably not worth it for you” — we’ll tell you that too.